After producing vaccines and treatments for acute COVID-19 in record time, researchers and drugmakers are turning to finding a cure for long COVID, a more elusive target marked by hundreds of different symptoms afflicting millions of people.
GeoVax vaccine targeting virus in two places shows promise; virus may become resistant to antibody drugs
Antibody Studies, BNT162b2 (Pfizer and BioNTech), Cell, Clinical Trials, COVID-19 Studies, Delta Variant (B.1.617.2; India), Genetics, GlaxoSmithKline, Immunosuppression, Janssen COVID-19 Vaccine (J&J), Medical Journals, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Mutations, New England Journal of Medicine, Omicron (B.1.1.529) (South Africa), R&D, Researchers, SARS-CoV-2 spike protein, The Lancet, The Lancet Microbe, Vir BiotechnologyAn experimental vaccine developed by GeoVax Labs Inc. succeeded in promoting development of antibodies that target two different sites on the virus in a small pilot study and was advanced to mid-stage clinical trials, researchers reported.
COVID-19 patients who receive one of the few antibody treatments that works against the Omicron variant must be carefully monitored because after the drug is infused, the virus may mutate and become resistant to it, researchers warned after seeing such cases with Delta variant patients.
Britain’s GSK halted enrollment and vaccination in three trials of the company’s experimental vaccine against the respiratory syncytial virus (RSV) in pregnant women, the latest setback in developing a vaccine for the microbe.
COVID-19 Update: Omicron BA.2 Raises Questions, FDA Limits GSK Antibody
BNT162b2 (Pfizer and BioNTech), CDC, Clinical Trials, Coronavirus Cases, Covid-19 Data, COVID-19 Studies, COVID-19 Vaccinations, FDA, GlaxoSmithKline, Monoclonal Antibodies, mRNA-1273/Moderna COVID-19 Vaccine (Moderna), Multisystem Inflammatory Syndrome in children (MIS-C), Omicron (B.1.1.529) (South Africa), Omicron BA.2, R&D, Sotrovimab, Teenagers, Vir BiotechnologyThe BA.2 subvariant of Omicron, which appears to be even more transmissible than Omicron, is accounting for more than a third of global COVID-19 cases. In other news, the U.S. Food and Drug Administration placed limits on the use of GlaxoSmithKline and Vir Biotechnology’s COVID-19 antibody therapeutic, sotrovimab.
The U.S. Food and Drug Administration said on February 23 GlaxoSmithKline and Vir Biotech’s COVID-19 antibody treatment should not be used in places with circulation of variants that are not susceptible to the drug.
French drugmaker Sanofi and the company’s British partner GlaxoSmithKline are seeking regulatory approval for their COVID-19 vaccine to be used as a booster, as well as a standalone two-dose shot, after several setbacks.
GlaxoSmithKline’s consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever.
GSK paused a late-stage trial of the company’s vaccine candidate against the respiratory syncytial virus (RSV) in pregnant women based on safety recommendations from an independent committee, the British drugmaker said on February 18.
GSK-Vir therapy has neutralizing activity against Omicron sub-variant, data shows
Antibodies, Broadly Neutralizing Antibodies (bNAbs), Clinical Data, Clinical Trials, Columbia University, Covid-19 Data, COVID-19 Studies, GlaxoSmithKline, Monoclonal Antibodies, Omicron BA.2, R&D, Researchers, Sotrovimab, Vir BiotechnologyAn antibody-based COVID-19 therapy developed by GSK and Vir Biotechnology retains neutralizing activity against the emerging BA.2 form of the Omicron coronavirus variant, according to data from a laboratory study cited by Vir on February 10.
COVID Update: Revisiting the Lab-Leak Theory and Under 5 Vaccination
Beijing, CDC, Children, China, Clinical Data, Clinical Trials, Covid-19 Data, COVID-19 Infections, COVID-19 Origins, COVID-19 Vaccinations, Emergency Use Authorization (EUA), GlaxoSmithKline, Heart Disease, Heart Problems, Janssen, Johnson & Johnson, Neutralizing Antibodies, New England Journal of Medicine, Omicron (B.1.1.529) (South Africa), Omicron BA.2, R&D, Scripps Research Institute, Vir BiotechnologyJane Qiu, a freelance science writer based in Beijing, published an overview of her efforts to investigate the lab-leak theory for the origin of COVID-19. In another update, the FDA’s Vaccines and Related Biological Products Advisory Committee is scheduled to meet on February 15 to discuss an amended Emergency Use Authorization for the Pfizer-BioNTech COVID-19 vaccine for children 6 months through 4 years of age.